American and European researchers publish study in Nature Medicine reporting a new, single treatment option for cystic fibrosis patients
Researchers from the George Washington University (GW), the University of Perugia, and the University of Rome have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin ?1 (T?1) is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients.
“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone,” said Allan L. Goldstein, Ph.D., co-author of the paper and Professor Emeritus in Residence of Biochemistry and Molecular Medicine at the GW School of Medicine and Health Sciences. “We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result.”
Cystic fibrosis is a genetic disease that causes persistent lung infections and limits the ability to breathe over time, and it affects approximately 70,000 worldwide and 30,000 in the U.S. alone. Cystic fibrosis is the result of mutations in the gene encoding the protein called the cystic fibrosis transmembrane conductance regulator (CFTR), which is important to maintain chloride-channel activity affecting the salt and water balance in the lungs. This mutation results in a misfolded CFTR protein, and its premature degradation leads to impaired chloride permeability and persistent lung inflammation.
Goldstein and co-authors Luigina Romani, Ph.D., M.D., at the University of Perugia and Enrico Garaci, M.D., at the University of Rome “San Raffaele,” both in Italy, published their results in Nature Medicine. They report that T?1, a synthetic version of a naturally occurring peptide first isolated from the thymus, corrects the multiple tissue defects found in the lungs and small intestines in a mouse model of cystic fibrosis, as well as the defects in the CFTR seen in cells isolated from cystic fibrosis patients. T?1 not only significantly reduces the inflammation seen in cystic fibrosis, but also increases CFTR maturation, stability, and activity. Due to this two-pronged action, T?1 offers a strong potential to be a single-molecule therapeutic agent to treat and stop the progression of cystic fibrosis.
Goldstein and colleagues first isolated and characterized T?1 as a biological response modifier with potent immune therapeutic activity in 1979. This research was done in large part at GW. Although the peptide is produced in small amounts in several peripheral lymphoid and non-lymphoid tissues, the highest concentrations of T?1 are found in the thymus. T?1, whose commercial name is Zadaxin, has been approved for clinical use for over 15 years in 35 countries in the treatment of patients with viral infections, immunodeficiency diseases, malignancies, and HIV/AIDS. Though not currently available in the U.S., it has an excellent safety profile and does not induce the side effects and toxicities commonly associated with most immunomodulatory agents.
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Yukon to cover 'miracle' cystic fibrosis drug's $300k price tagon October 15, 2021 at 5:23 pm
Trikafta will be available free of cost to Yukoners 12 and over with cystic fibrosis within two months. The territory has now joined 6 provinces in covering the drug's $300k price tag.
- Maritimers with cystic fibrosis closer to drug accesson October 15, 2021 at 4:07 pm
After fighting for it for years, Maritimers with cystic fibrosis are getting closer to having better access to what many call a life-changing drug treatment.
- Coverage for cystic fibrosis medication endorsed in legislatureon October 15, 2021 at 1:00 pm
Yukoners with cystic fibrosis may soon have a new drug treatment covered in the territory. Legislators unanimously endorsed a motion on Sept. 13 from NDP MLA Annie Blake calling on the house to cover ...
- Cystic fibrosis 'wonder drug' now covered by P.E.I.on October 15, 2021 at 12:53 pm
The Prince Edward Island government is now providing medical coverage for a drug which helps improve the life of Islanders with cystic fibrosis.
- Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.on October 15, 2021 at 11:58 am
BACKGROUND: There has been increasing concern since 1979 about the emergence of Pseudomonas cepacia (Burkholderia cepacia) in patients with cystic fibrosis in the UK and elsewhere. Colonisation of the ...
- Vale Andrew Prowse: Prominent Canberran with Cystic Fibrosis dieson October 15, 2021 at 11:00 am
Heidi Prowse knew when she married her husband Andrew they would never grow old together. Andrew was born with cystic fibrosis, a genetic disease that attacks the lungs and digestive system. There is ...
- Nova Scotia to cover the cost of cystic fibrosis drug Trikaftaon October 15, 2021 at 7:39 am
Nova Scotia’s health minister says the government will cover the cost of the cystic fibrosis drug Trikafta. Michelle Thompson says she expects the drug to be on the provincial formulary by the end of ...
- Arizona man with cystic fibrosis complete historic Ironman raceon October 14, 2021 at 4:02 pm
A San Tan Valley man made history when he recently finished an entire Ironman race – with cystic fibrosis. He’s the first man ever to do that without a lung transplant. “It’s definitely a big deal,” ...
- Study for better understanding of cystic fibrosison October 10, 2021 at 10:50 pm
According to Cystic Fibrosis Canada, CF is the most common fatal genetic disease affecting Canadian children and young adults. There is presently no c..
via Bing News